Health service and government policies on the licensing, provision and reimbursement of oral pre-exposure prophylaxis (PrEP). Expert guidelines, based on research evidence, to help clinicians provide care to PrEP users.

PrEP policies and guidelines: latest news

PrEP policies and guidelines features

PrEP policies and guidelines news from aidsmap

More news

PrEP policies and guidelines news selected from other sources

  • LGBT+ health adviser urges Britain to make HIV-prevention drug free

    Britain’s first national adviser for LGBT+ health has said the roll-out of a highly effective HIV prevention pill could save hundreds of thousands of pounds for the country’s publicly funded health authority. In an exclusive interview Michael Brady, who will take up the role on April 1, said a planned roll-out of pre-exposure prophylaxis (PrEP) - a once-daily pill that protects against HIV – in England would prove cost effective “very quickly”.

    18 March 2019 | Reuters
  • Obituary: Mags Portman died on February 6th

    The sexual-health pioneer and campaigner for access to PrEP was 44

    15 March 2019 | The Economist (requires free registration)
  • Jean-Michel Molina, MD, on Biomedical Failures of PrEP: Rare, But Serious

    "There are multiple reasons for PrEP failures and they could be at any point in the PrEP continuum of care. From people who may not use their pills as recommended, to a health care system that is not able to provide access to PrEP for people in need, it could be also the physicians who are not ready to prescribe PrEP or not aware that they could use PrEP for preventing HIV in high-risk patients. It could be also the test that we use sometimes that are not able to detect acute HIV infection. And, if you start PrEP in someone with acute HIV infection you will see more resistance."

    14 March 2019 | Contagion Live
  • Trump’s Proposed Budget Undermines His H.I.V. Plan, Experts Say

    Strategies abound to end the AIDS epidemic, but expense — mostly for drugs costing up to $50,000 a year — is the inevitable obstacle.

    14 March 2019 | The New York Times
  • Gilead's Descovy snared its PrEP data, but can it stand up to Truvada generics?

    Gilead Sciences has the data it’ll need to start transitioning patients taking Truvada for PrEP over to Descovy, a drug with a longer patient life. But once Truvada generics hit, it might be a different story.

    14 March 2019 | FiercePharma
  • Sadiq Khan: Cash row is denying Londoners access to HIV ‘wonder drug’

    The London mayor said: “I’m shocked that the Government is failing to provide local authorities in London with the funding they need to provide PrEP to all those who could benefit.”

    12 March 2019 | Evening Standard
  • How Many More Must Needlessly Contract HIV Before We Ensure Proper Access To PrEP?

    Local authorities are legally responsible for providing information and services that can help prevent HIV. We are calling on local authorities in London to urgently double the number of places offered to them as part of the trial. Other parts of England have shown decisive leadership on PrEP access, it’s time for London to do the same.

    12 March 2019 | Huffington Post
  • Here's how to get onto England's PrEP trial

    Will Nutland of Prepster explains.

    06 March 2019 | Gay Star News
  • SF health officials embrace non-daily PrEP dosing regimen

    The San Francisco Department of Public Health advised HIV care providers that they should consider PrEP 2-1-1 "for men who have sex with men (MSM) who are ambivalent about daily pre-exposure prophylaxis for HIV (PrEP)."

    28 February 2019 | Bay Area Reporter
  • Councils in London may block additional PrEP places proposed for gay and bisexual men

    NHS England announced today that whilst the PrEP Impact trial will double the number of places on the trial in clinics outside London, local authority commissioners in London are still considering what proportion of the proposed additional places they wish to accept. Fifty per cent of PrEP Impact Trial places are for London clinics.

    28 February 2019 | National AIDS Trust
More news
Tell us why you visited aidsmap today
minimise

Could you help us by answering three questions on why you’ve visited aidsmap today?

You can close this questionnaire and come back to it later. Just click on the pink circle.

What prompted you to visit aidsmap today?

What exactly are you looking for? What specific questions do you need answered?

Have you found what you were looking for?

close

Thank you for your feedback

Thank you very much for taking time to fill in this questionnaire. NAM really values your feedback. It helps make the information we provide better.

If you have any other comments on the content of this website, we would be interested to hear from you. Please email info@nam.org.uk.

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.